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This editorial refers to ‘Predicting adverse events during
angiotensin receptor blocker treatment in heart failure:
results from the HEAAL trial’, by M.S. Kiernan et al., pub-
lished in this issue on pages 1401–1409.
In 2009, the HEAAL investigators1 reported that losartan 150 mg/
day reduced the rate of death and admissions for heart failure with
reduced ejection fraction (HFREF) compared with patients receiv-
ing losartan 50 mg/day, the dose previously recommended and
evaluated in ELITE II2 to compare losartan with captopril. This im-
portant contribution pointed out the necessity to determine the
effective dose of a drug in patients with HFREF rather than
relying upon the dose used to lower blood pressure in patients
with essential hypertension. In this issue of the journal, the
HEAAL investigators3 report that investigator-reported adverse
events (AEs), including kidney impairment, hyperkalaemia, and
hypotension, were associated with an increased risk of death com-
pared with those patients who did not experience them, and that
these AEs were more frequent in the losartan 150 mg than the
losartan 50 mg group. The median serum creatinine on the day
of their investigator-reported AE was 1.8 mg/dL, potassium
5.8 mmol/L, and systolic and diastolic blood pressures were 86
and 60 mmHg, respectively. Independent of the dose of losartan,
these AEs were more frequent in older patients, those receiving
an aldosterone blocker, and in those who reported the incident
AE as the reason for intolerance to angiotensin-converting
enzyme inhibitor therapy, one of the criteria for treatment with
losartan. Baseline levels of serum creatinine were predictive of sub-
sequent renal impairment, while entry levels of serum potassium
predicted the occurrence of hyperkalaemia, and baseline systolic
blood pressure predicted subsequent hypotension. Diabetes melli-
tus, baseline haemoglobin, and diuretic use were also predictive of
subsequent kidney impairment and hyperkalaemia. However, while
these factors were predictive of subsequent AEs, the association
between investigator-reported kidney impairment, hyperkalaemia,
and hypotension and the excess risk of subsequent death and
first hospitalization for HF was independent of these baseline
factors. Also of note was the finding that the frequency of these
AEs continued to increase over time and was not limited to the
period surrounding initiation of therapy with losartan. On the
basis of these findings, the HEAAL investigators3 suggest close
monitoring in patients with the baseline risk factors they identified
and in patients treated with losartan 150 mg/day.
The finding that these AEs were associated with an increase in
mortality, while not surprising, is nevertheless of importance and
raises the issue of how we can avoid these AEs and how we
should respond once they occur. It is important to emphasize
that while there were significantly more AEs associated with the
use of losartan 150 than 50 mg/day the strategy of losartan
150 mg significantly reduced cardiovascular events in comparison
with 50 mg1 and that the same AEs were associated with an in-
crease in mortality when they occurred in patients on losartan
50 mg. While avoiding these AEs that were associated with an in-
crease in mortality is desirable, it should be pointed out that these
AEs are often difficult to predict in an individual patient and may be
the cost of some strategies shown to be effective in reducing total
mortality in patients with HFREF. One might conclude given the
dictum ‘primun non nocere’ that since losartan 150 mg/day is asso-
ciated with an increase in the incidence of AEs that resulted in an
increase in mortality, it is better to avoid this strategy, especially in
individuals at high risk for the development of these AEs with
losartan such as those with chronic kidney disease, diabetes melli-
tus, or low haemoglobin, the very old, and those on an aldosterone
blocker. These are, however, the very individuals who are at great-
est risk and most in need of effective therapy to reduce their car-
diovascular risk. Many clinicians have used this reasoning and have,
for example, avoided the use of indicated aldosterone blockers in
patients with HFREF4 due to the fear of inducing hyperkalaemia,
despite the evidence that aldosterone blockers reduce cardiovas-
cular events even in these high-risk individuals.5 While close mon-
itoring should be instituted when prescribing losartan or similar
agents to patients with the baseline risk factors identified by the
HEAAL investigators,3 the failure to attempt initiation may place
the patient at greater risk than that associated with the develop-
ment of these AEs.
A more difficult question is what should one do once these AEs
occur in a patient with HFREF. Our initial impulse might be to with-
hold or reduce the dose of the drug thought to be responsible for
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the AE, such as losartan 150 mg/day or an aldosterone-blocking
agent. On closer reflection, this impulse might be wrong. As the
HEAAL investigators3 point out, the occurrence of an AE such
as hyperkalaemia or renal dysfunction might reflect progression
of the underlying disease process and therefore might be an indi-
cation to continue the culprit drug rather than withdrawing it or
reducing the dose. For example, aldosterone-blocking agents are
known to be associated with an increased risk of hyperkalaemia,
and it has been suggested that their dose be reduced if the
serum potassium is 5.5 mmol/L and withheld if at any time on a
non-haemolysed blood sample it is ≥ 6.0 mmol/L. Although this
approach is reflected in current guidelines,6,7 recent evidence
from RALES8 suggests that the use of spironolactone was asso-
ciated with a reduction in mortality up to a serum potassium
level of 6.0 mmol/L. Withholding losartan 150 mg or an aldoster-
one blocker from an otherwise indicated patient with HFREF
and hyperkalaemia might in fact expose that patient to a far
greater risk of death than that associated with hyperkalaemia.
The risk of death associated with a given level of serum potassium
is difficult to judge, and depends upon several factors including the
rate of increase in serum potassium, pH, and serum calcium con-
centration. Unfortunately, the electrocardiogram has proven to
be a poor guide to the risk of death associated with hyperkalaemia
in an individual patient.9 We need other markers to help us identify
the level of serum potassium associated with an increased cardio-
vascular risk in an individual patient. Possibly measurement of
tissue potassium as reflected by red blood cell potassium concen-
tration10 will be of value in this regard.
The implications regarding the cardiovascular risks associated
with hypotension might be different from those associated with
hyperkalaemia or renal impairment. Although hypotension was
clearly associated with an increased risk of death in HEAAL
whether on losartan 150 mg or 50 mg/day,3 it is likely that many
episodes of clinically significant hypotension were undetected.
Mak et al.,11 using ambulatory blood pressure monitoring in
patients with HF treated with a neurohumeral blocking agents,
noted a relatively high incidence of nocturnal hypotension that
was unsuspected based upon office blood pressure monitoring
or patients’ symptoms. These nocturnal hypotensive episodes
were associated with an increased cardiovascular risk. The level
of hypotension at which one should be concerned in an individual
patient with HF is, however, uncertain and may depend on the
presence or absence of manifest and/or occult vascular disease.
Possibly the use of biomarkers such as high sensitivity troponin
might be of value in determining in an individual patient if a given
degree of hypotension has been associated with ischaemic
damage and therefore predisposes them to a subsequent increase
in mortality. Withholding life-saving therapy such as losartan
150 mg/day after an episode of hypotension not associated with
ischaemic damage may place the patient at far greater risk than con-
tinuing it. On the other hand, if one can detect evidence of tissue
damage associated with the hypotensive episode, the proper
response would be to reduce the dose or withhold the drug.
In conclusion, while the finding that investigator-reported AEs in
HEAAL3 were associated with an increase in mortality is not sur-
prising, what is surprising is how little we know about the patho-
physiology associated with the induction of these AEs, how to
avoid them without exposing patients to an even greater risk,
when to reduce the dose or withhold the suspected culprit
drug, and when to continue it despite the occurrence of these
AEs. This is an area for further investigation, and the HEAAL inves-
tigators should be congratulated for bringing this issue into focus.
Good poker players understand that those who win most consist-
ently know when to hold and when to fold. Similarly, good clini-
cians understand when to withhold a drug or reduce its dose
and when to continue therapy despite the occurrence of these
AEs. Some further insight into the means of evaluating the risk
of these AEs in an individual patient might make us all winners
and avoid exposing our patients to unnecessary risk.
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